Answers are grounded in this paper and cite their sources.
Objective: Liver fibrosis is a common pathological condition that can lead to liver failure. Previous studies demonstrated that 5-fluorouracil (5-FU) is an effective agent in preventing fibrosis. This experimental study aimed to evaluate the efficacy of 5-FU therapy on liver fibrosis in rats. Material and Methods: Thirty-eight rats were divided into 3 groups: Group 1 (sham-operated, n=10), the bile duct (BD) was exposed but not ligated; Group 2 [bile duct ligation (BDL)-saline, n=14], the BD was ligated and normal saline solution was given; Group 3 (BDL-5-FU, n=14), the BD was ligated and treated with 5-FU. The liver and blood samples were harvested at postoperative day 21. Liver function analyses, tissue hydroxyproline (HP) content, and serum and tissue transforming growth factor beta 1 (TGF-β1) levels were determined. The liver sections were analyzed and percentage of tissue collagen content was measured. Results: There were no significant differences between the groups in terms of tissue (p=0.748) and serum (p=0.123) levels of TGF-β1. Mean HP level in the sham-operated, BDL-saline, and BDL-5-FU groups were 253±42 ng/L, 360±32 ng/L and 305±41 ng/L, respectively. 5-FU significantly decreased HP level (p=0.036). Mean percentage of collagen content in the sham-operated, BDL-saline, and BDL-5-FU groups were 0.99±0.39%, 4.92±1.03%, and 2.62±0.64%, respectively. 5-FU significantly reduced collagen accumulation (p<0.001). Conclusion: 5-FU has a preventive effect on liver fibrosis in rats. This result suggests that 5-FU can be a potential agent for prevention of liver fibrosis in clinical practice.
No takes yet. Share an insight, caveat, or question.
OKAY et al. (2022) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: